Cargando…
O012: Can DAV132, a medical device targeting an adsorbent to the late ileum, decrease significantly the impact of antibiotics on the fecal microbiota?
Autores principales: | Grall, N, Chachaty, E, Sayah-Jeanne, S, de Gunzburg, J, Andremont, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687688/ http://dx.doi.org/10.1186/2047-2994-2-S1-O12 |
Ejemplares similares
-
LB-5. DAV132 Protects Intestinal Microbiota of Patients Treated with Quinolones, a European Phase II Randomized Controlled Trial (SHIELD)
por: Ducher, Annie, et al.
Publicado: (2020) -
An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones
por: Vehreschild, Maria J. G. T., et al.
Publicado: (2022) -
Change in Bacterial Diversity of Fecal Microbiota Drives Mortality in a Hamster Model of Antibiotic-induced Clostridium difficile Colitis
por: Burdet, Charles, et al.
Publicado: (2017) -
Mathematical Modeling of Bacterial Kinetics to Predict the Impact of Antibiotic Colonic Exposure and Treatment Duration on the Amount of Resistant Enterobacteria Excreted
por: Nguyen, Thu Thuy, et al.
Publicado: (2014) -
O012. Intra-variability of the characteristics of migraine attacks
por: Viana, Michele, et al.
Publicado: (2015)